GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regencell Bioscience Holdings RGC · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.63

+6.74%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Regencell Bioscience Holdings

Its shares trade under the ticker RGC. It has been listed since 16 July 2021. In the fiscal year to 30 June 2018, it reported revenue of $3.16bn and net income of $112.3m. At that date it held total assets of $2.84bn and shareholders' equity of −$855.8m.

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
16 Jul 2021
Employees
10
Head office
9/F CHINACHEM LEIGHTON PLAZA, HONG KONG
Incorporated in
E9
Classification
Medicinal Chemicals & Botanical Products
Filer status
Large accelerated filer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 10 employees as per official data
  • Company focuses on research, development, and commercialization of traditional Chinese medicine
  • Company has launched three liquid-based standardized TCM formulae for ADHD and ASD patients

Weaknesses

  • Company has only 10 employees, indicating limited workforce capacity
  • Company's city location is unknown, which may affect operational transparency
  • Company's website is provided but no additional details about operations are available

Opportunities

  • Expansion of TCM formulae for ADHD and ASD patients could attract new markets
  • IPO in 2021 may provide capital for further research and development
  • Growing interest in traditional Chinese medicine could increase market demand

Threats

  • Unreliable source data contradicts official employee count (10 vs 12)
  • Lack of detailed information about company operations may deter investors
  • Dependence on TCM formulae for specific conditions may limit market reach

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.